Bruker Announces Quarterly Dividend

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company’s common stock. The dividend will be paid on September 17, 2021 to stockholders of record as of September 1, 2021. About Bruker Corporation... Read more

Bruker Reports Second Quarter 2021 Financial Results

Q2 2021 revenue growth of 34.4% year-over-year; organic revenue growth of 27.2% Q2 2021 GAAP EPS of $0.38; non-GAAP EPS of $0.44, compared to $0.21 in Q2 2020 Strong financial performance in the Bruker Scientific Instruments and BEST businesses drives a further increase in fiscal year 2021 guidance BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR)... Read more

PerkinElmer Expands KRAS Oncology Drug Discovery Assays with New Ready-to-Use AlphaLISA Kits

Mailing addressesCorrespondence should be mailed to:ComputershareP.O. Box 505000Louisville, KY 40233 Overnight correspondence should be sent to:Computershare462 South 4th Street, Suite 1600Louisville, KY 40202 Shareholder website www.computershare.com/investorShareholder online inquirieswww-us.computershare.com/investor/Contact Read more

PerkinElmer Announces Financial Results for the Second Quarter of 2021

Revenue of $1.228 billion; 51% reported growth; 41% organic growth GAAP EPS from continuing operations of $2.19; Adjusted EPS of $2.83 Initiates Third Quarter and Raises Full-Year Revenue and Earnings Guidance Announces Agreement to Acquire BioLegend – Leading Antibody & Research Reagent Provider Earnings Call Moved to Today at 8:00 a.m. Eastern Time; Dial-in Information... Read more

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

Transformative deal significantly scales leading position in life science to accelerate legendary discoveries in precision medicine Leader in antibody development with highly complementary, innovative portfolio in emerging, high-growth areas of biologics, cell and gene therapy, proteogenomics, and recombinant proteins Commercial synergy opportunity to accelerate life science growth with potential benefits for diagnostics franchise Annual BioLegend... Read more

PerkinElmer’s COVID-19 RT-PCR Test Kit Receives FDA Emergency Use Authorization for Saliva as Specimen Type

Non-invasive sampling method makes it easier to use the highly sensitive molecular test manufactured by PerkinElmer WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that the U.S. Food and Drug Administration (FDA) has authorized the PerkinElmer® New Coronavirus Nucleic Acid Detection Kit for an additional indication that permits... Read more

Danaher Reports Second Quarter 2021 Results

WASHINGTON, July 22, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the second quarter 2021.  All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended July 2, 2021, net earnings were $1.7 billion, or $2.28 per diluted common share which represents an 84.0% year-over-year... Read more

Bruker Announces Date and Time of Second Quarter 2021 Earnings Release and Webcast

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2021 financial results on Monday, August 2, 2021, after the market closes. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can... Read more